Clinical Trial Update: Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy [Phase 3]

View source ↗

Summary

Phase 3 dose-response study of Zonegran (zonisamide) in patients with newly diagnosed epilepsy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complex Partial Epilepsy

Drugs mentioned

• Zonegran (zonisamide)

Snippet

Sponsor: Eisai Inc. | Conditions: Epilepsy, Complex Partial | Phase 3 | Status: COMPLETED